Prosecution Insights
Prosecution Insights
8 pending office actions • 3 clients • 8 examiners • 7 art units • 0 of 8 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (38%) |
| §112 only | 1 (12%) |
| No statute on record | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COPPINS, JANET L | 1 | 73.4% | +25.0% |
| MAEWALL, SNIGDHA | 1 | 58.8% | +9.7% |
| ISMAIL, REHANA | 1 | 78.9% | +30.2% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.3% | +24.5% |
| SCHMIDT, IZABELA MARIA | 1 | 63.1% | +53.5% |
| CORNET, JEAN P | 1 | 42.0% | +47.8% |
| SEITZ, ANTHONY JOSEPH | 1 | 68.8% | +28.3% |
| MARTIN, PAUL C | 1 | 42.0% | +21.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17596466 | HDAC3 CATALYTIC INHIBITOR DEVELOPMENT AND USES THEREOF | SEITZ, ANTHONY JOSEPH | 85d overdue |
| 16558488 | HIGH POTENCY PANCREATIN PHARMACEUTICAL COMPOSITIONS | MARTIN, PAUL C | 26d overdue |
| 18191589 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | ISMAIL, REHANA | 12d |
| 18189092 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | WHITE, DAWANNA SHAR-DAY | 27d |
| 17628794 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | CORNET, JEAN P | 28d |
| 17789047 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | SCHMIDT, IZABELA MARIA | 30d |
| 18553988 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | COPPINS, JANET L | 35d |
| Client (Assignee) | Pending OAs |
|---|---|
| DANA-FARBER CANCER INSTITUTE, INC. | 5 |
| AbbVie | 2 |
| NEW YORK UNIVERSITY | 1 |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1612 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| 1621 | 1 |
| 1629 | 1 |
| 1653 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18553988 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | COPPINS, JANET L | 1628 | §112 | Non-Final OA | 35d | Pending | Oct 04, 2023 |
| 18215098 | DIGESTIVE ENZYME COMPOSITION SUITABLE FOR ENTERAL ADMINISTRATION | Allergan Pharmaceuticals International Limited | MAEWALL, SNIGDHA | 1612 | Other | Final Rejection | 99d overdue | Pending | Jun 27, 2023 |
| 18191589 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | ISMAIL, REHANA | 1625 | Other | Non-Final OA | 12d | Pending | Mar 28, 2023 |
| 18189092 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | WHITE, DAWANNA SHAR-DAY | 1627 | §103 | Non-Final OA | 27d | Pending | Mar 23, 2023 |
| 17789047 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | New York University | SCHMIDT, IZABELA MARIA | 1621 | Other | Final Rejection | 30d | Pending | Jun 24, 2022 |
| 17628794 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | CORNET, JEAN P | 1628 | §103 | Non-Final OA | 28d | Pending | Jan 20, 2022 |
| 17596466 | HDAC3 CATALYTIC INHIBITOR DEVELOPMENT AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | SEITZ, ANTHONY JOSEPH | 1629 | §103 | Final Rejection | 85d overdue | Pending | Dec 10, 2021 |
| 16558488 | HIGH POTENCY PANCREATIN PHARMACEUTICAL COMPOSITIONS | Allergan Pharmaceuticals International Limited | MARTIN, PAUL C | 1653 | Other | Non-Final OA | 26d overdue | Pending | Sep 03, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial